MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Varex Imaging Corporation Cost of Revenue 2011-2026 | VREX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Varex Imaging Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 554 M | 554 M | 603 M | 576 M | 547 M | 548 M | 524 M | 520 M | 445 M | 372 M | 382 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 603 M | 372 M | 511 M |
Quarterly Cost of Revenue Varex Imaging Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 140 M | - | 136 M | 136 M | 131 M | - | 142 M | 140 M | 133 M | - | 156 M | 156 M | 142 M | - | 141 M | 144 M | 134 M | - | 137 M | 139 M | 139 M | 423 M | 145 M | 139 M | - | 393 M | 136 M | 131 M | 126 M | 374 M | 128 M | 131 M | 115 M | 307 M | 111 M | 97.2 M | 98.6 M | 269 M | 88.4 M | 98.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 423 M | 88.4 M | 163 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.19 | 5.67 % | $ 887 M |  USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.73 | 1.48 % | $ 887 M |  Israel |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 34.86 | 4.68 % | $ 5.19 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.51 | 5.32 % | $ 269 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.15 | -1.78 % | $ 1.82 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.1 | 0.33 % | $ 326 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 31.75 | 3.15 % | $ 1.46 B | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 59.61 | -4.85 % | $ 1.77 B |  Costa-rica |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.63 | 1.92 % | $ 1.14 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 82.02 | -0.58 % | $ 48 B | USA |
 |
Electromed
ELMD
|
14 M | $ 24.49 | 5.2 % | $ 207 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.67 | 2.06 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.3 | 6.48 % | $ 3.59 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.06 | 0.98 % | $ 1.25 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.43 | 5.48 % | $ 726 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 10.37 | 4.64 % | $ 1.4 B | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 99.2 | -0.3 % | $ 1.26 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.73 | 3.32 % | $ 139 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.47 | -0.3 % | $ 386 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 52.16 | -2.9 % | $ 1.53 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 63.24 | 1.69 % | $ 3.45 B |  Britain |
 |
Medtronic PLC
MDT
|
11.6 B | $ 87.17 | 1.13 % | $ 112 B | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.39 | 2.21 % | $ 56.6 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.71 | 0.08 % | $ 29.7 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |